A Agilent Technologies Inc.

Agilent Receives 2017 Scientists' Choice Award for Best New Clinical Laboratory Product

Agilent Technologies Inc. (NYSE: A) has received a 2017 Scientists’ Choice Award for Best New Clinical Laboratory Product: the IQFISH Panel for Lung Cancer. The IQFISH panel for lung cancer makes it easier for pathology labs to integrate fast, high-quality FISH (fluorescent in situ hybridization) into their IHC workflows.

The announcement was made during a special ceremony held during the AACC Annual Scientific Meeting & Clinical Lab Expo 2017 held early August in San Diego, USA. AACC highlights the most exciting clinical developments from institutions all over the world. As it does each year, scientists around the world were invited to participate in the Scientists’ Choice Awards by nominating, voting and reviewing online.

“We are delighted and honored to receive this award, especially because the voters were scientists themselves,” says Jeff Heimburger, head of genomics marketing for Agilent. “Not only is this a recognition of product quality and innovation, it also shows that we’re listening to our customers and developing the right products that help them fight cancer.”

Non-small-cell lung cancer can involve certain genetic aberrations. The IQFISH panel for lung cancer can help detect rearrangements involving those genes, yielding information that can help guide treatment options. With this technology, multiple FISH slides can be processed in just four hours, whereas traditional FISH can take two or more days.

The IQFISH panel launched in Europe in 2016 and is CE-IVD labeled. It is not available for sale in the U.S.

The annual Scientists' Choice Awards celebrate the laboratory products and manufacturers that make a difference to the industry. SelectScience began the Scientists’ Choice Awards in 2007 to enable scientists to voice their opinions on the best laboratory products. Scientists are then invited to vote for their favorite products within each category, and the winners are announced at scientific conferences.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to its customers’ most challenging questions. The company generated revenues of $4.20 billion in fiscal 2016 and employs about 13,000 people worldwide. Information about Agilent is available at www.agilent.com.

EN
05/09/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Agilent Technologies, Inc.: Key facts and statistics - fiscal 2025

A summary company profile, detailing Agilent Technologies, Inc.’s business operations and financial highlights.

Agilent Technologies, Inc. - October 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Agilent Technologies, Inc.: Update to credit analysis

Our credit view of this issuer reflects its low financial leverage, against its high proportion of revenue from costly equipment sales, which has exposure to cyclical demand fluctuations

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Agilent Technologies, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 11 December 2025 in which we reassessed the appropriateness of the ratings in th...

Agilent Technologies Inc: 1 director

A director at Agilent Technologies Inc sold 2,600 shares at 149.812USD and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch